Insurance & Reinsurance equity research

Explore the most viewed and latest equity research and media content for companies within the Insurance & Reinsurance sector. Stocks in this sector provide insurance and broker services within life insurance, full line, and reinsurance.

Insurance & Reinsurance equity research

Explore the most viewed and latest equity research and media content for companies within the Insurance & Reinsurance sector. Stocks in this sector provide insurance and broker services within life insurance, full line, and reinsurance.

Latest Content

Good 2016 results, dividend increased

  • 17 Feb 17

Preliminary net profit attributable to shareholders increased by 4% to €6.88bn for FY2016 compared to the year before. Premiums earned were mainly unchanged at €70.4bn in FY2016. Interest and similar income was down by 2.2% to €22.15bn and realised investment rose by 2.6% to €6.9bn for FY2016. Total operating income was flat at €106.1bn in FY2016 compared to 2015. Claims increased by 3% to €53.2bn and total operating expenses declined by 0.3% to €95.2bn. Operating profit (under Allianz’s definition) increased from €10.74bn for FY2015 to €10.83bn for FY2016. Pre-tax profit rose by 1% to €10.3bn for FY2016. Third-party assets under management rose by 6.7% to €1,361bn in FY2016. Net new money outflow was €20bn in 2016 compared to €107bn in 2015. Shareholders’ equity rose by 6.6% to €67.3bn at the end of 2016 compared to 2015. The solvency II ratio was 218% at the end of 2016 compared to 200% for 2015. The dividend proposal rose from €7.30 for FY2015 to €7.60 per share for FY2016. The new operating profit target for FY2017 is €10.8bn plus or minus €0.5bn. Allianz has decided to launch a share buy-back programme with a volume of up to €3bn as part of a previously announced plan to return unused capital from the group’s external growth budget from the period 2014 to 2016. The buy-back programme is envisaged to start on 17 February 2017, and to last no longer than 12 months. Allianz SE will cancel all repurchased shares.

 

Providers

30 Providers with research from over 351 professional analysts